Recent News June 12, 2009 Investigator from Feinberg Cardiovascular Research Institute participates in announcement of new landmark tobacco regulation legislation. Dr. Hossein Ardehali, an Investigator at Feinberg Cardiovascular Research Institute, served as an advocate for the American Heart Association in today's announcement of a landmark bill that provides for tighter regulation of tobacco. See news and photos at Illinois Advocacy Beat. April 9, 2009 Three Feinberg Cardiovascular Research Institute investigators receive new RO1 grant awards from the National Heart, Lung, and Blood Institute of the National Institutes of Health. Feinberg Cardiovascular Research Institute is pleased to announce that three of its investigators were awarded new research grants from NHLBI to study various topics in cardiovascular disease. Dr. Rishi Arora was awarded a RO1 grant entitled "Disruption of Autonomic Pathways in the Left Atrium by Inhibition of G-Proteins". This grant will provide over $2.2 million of funding over a five year project period. Dr. Raj Kishore was awarded a RO1 grant entitled "TNF mRNA Stability and Restenosis". His grant will provide over $1.5 million of funding over a four year project period. Dr. Douglas Losordo was awarded a RO1 grant entitled "Novel Approaches to Ischemic Tissue Repair". Dr. Losordo's grant will provide over $1.5 million of funding over a four year project period. We congratulate our investigators on this notable achievement. March 30, 2009 Feinberg Cardiovascular Research Institute researcher presents evidence that a patient's own stem cells could be used for treatment of heart disease. Preliminary data presented on March 28 as a late-breaking abstract at the American College of Cardiology's 58th annual scientific session from the largest CD34+ adult stem cell study for heart disease has shown the first evidence that delivering a potent form of autologous (from the patient) adult stem cells into the heart muscle of patients with severe angina may result in less pain and improved exercise tolerance.
The six-month, Phase II data were presented by principal investigator Douglas Losordo, M.D., director of the Feinberg Cardiovascular Research Institute at Northwestern University's Feinberg School of Medicine and of the Program in Cardiovascular Regenerative Medicine at Northwestern Memorial Hospital. The trial was sponsored by Baxter International Inc. (click link to read the entire press release) A video interview of Dr. Douglas Losordo discussing these results can be viewed at Cardiosource. January 30, 2009 Three Feinberg Cardiovascular Research Institute scientists receive prestigious grant awards from American Heart Association  | | From left: Jörn Tongers, Rongxue Wu, and Prasanna Krishnamurthy |
Three postdoctoral researchers at Feinberg Cardiovascular Research Institute have been awarded research grants from American Heart Association to pursue exciting, original research in cardiovascular disease. Rongxue Wu, MD, PhD was awarded a two year grant award for her project entitled "Role of the Mitochondrial ATP-Binding Cassette Protein-2 in Cellular Protection. Rongxue works under the direction of Dr. Hossein Ardehali. Jörn Tongers, MD was awarded a two year grant award for his project entitled "Retention and Maintenance of Progenitor Cells in the Ischemic Target Region by Bioactive, Self-Assembling Nanofibers". Jörn works under the direction of Dr. Douglas Losordo. Prasanna Krishnamurthy, PhD was awarded a four year grant for his project entitled "Mechanisms of IL-10 Mediated Suppression of Inflammation". Prasanna works under the mentorship of Dr. Raj Kishore. |
Director, Feinberg Cardiovascular Research Institute
On behalf of the faculty and staff of the Feinberg Cardiovascular Research Institute, I welcome you to our Web site and thank you for your interest in learning about our programs. Originally established in 1988, the Feinberg Cardiovascular Research Institute is dedicated to pursuing an understanding of the fundamental molecular and cellular processes underlying cardiovascular disease, the largest contributor to morbidity and mortality in the United States. Though tremendous strides have been made in recent years in our understanding and treatment of cardiovascular disease, much work remains to be done. Our investigators at Feinberg Cardiovascular Research Institute are exploring complex problems at the vanguard of modern cardiovascular research, including basic cellular signaling pathways and their contributions to disease, the use of stem cells in regenerative medicine, and diagnostic and imaging technologies critical to patient care. As our Institute grows and evolves, we will continue to build expertise and infrastructure to support translational research, providing a more productive route for transforming basic laboratory discoveries into new treatment options for patients. |
